Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP net loss of -$18.0M compared to the expected -$15.4M, and GAAP EPS of -$0.19 vs. -$0.16 expected. The variance was driven by higher-than-anticipated clinical trial costs as the company accelerated its registrational Phase 3 PTCL and Phase 2 atopic dermatitis trials for soquelitinib. Despite the earnings miss, the company bolstered its balance sheet significantly, ending the quarter with $215.2M in cash, providing a runway into Q2 2028.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Corvus Pharma(CRVS) the EBIT is -19.3 M (-88.08%), Miss estimate;the EPS is -0.19 (-90%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B88.08%
-0.02B59.41%
-0.00B28.67%
EPSMiss expectations
-0.1990.00%
-0.159159.12%
-0.030930.88%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf